Text Size

Twenty-four-hour intraocular pressure control with omidenepag isopropyl 0.002% in patients with glaucoma and ocular hypertension

Shiratori N., Nishio Y., Takeda A., Sugimoto S., Takazawa K., Otsuka N., Ishida N., Shii D., Hori K., Nakamoto K.


  • 2021
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Nippon Medical School, Tokyo, Japan; Shinanozaka Clinic, Tokyo, Japan; Japan Medical Affairs Group, Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.


Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.


The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022